Business
BD is a global medical technology company selling medical supplies, devices, laboratory equipment, and diagnostic products to healthcare institutions, physicians, researchers, clinical laboratories, pharmaceutical companies, and the public.
BD grew revenue, but net income slipped and the Waters separation adds another execution test.
The read at a glance✓ Audited against SEC data
- Growth — Revenue +8.2% to $21.84BOK
- Profitability — Net income -1.6% to $1.68BWatch
- Cash quality — FCF not available; capex +4.8%Watch
- Margins — Net margin -77 bpsWatch
- Capital — Buybacks +100.0%; dividends +8.7%Watch
- Insiders — 1 open-market buy / 21 sellsWatch
Where the revenue comes from
Fiscal 2025, as BECTON DICKINSON & CO reports it. History and quarterly detail are in the app.
- Medical$11.5B
- Interventional$5.2B
- Life Sciences$5.2B
Leadership changes
From BECTON DICKINSON & CO's own filings, the day they're filed.
- Jacqueline Wright · Directors · appointmenteff. 2025-12-01
- Robert L. Huffines · Directors · appointmenteff. 2025-12-01
- Gregory J. Hayes · Directors · appointmenteff. 2025-03-26
Latest filings
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-07-22
- 8-K · Company announcement2026-05-29
- 8-K · Company announcement2026-05-20
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BECTON DICKINSON & CO, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.